Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?
出版年份 2018 全文链接
标题
Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2018-08-07
DOI
10.1111/dom.13488
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Inflammageing and metaflammation: The yin and yang of type 2 diabetes
- (2018) Francesco Prattichizzo et al. AGEING RESEARCH REVIEWS
- Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes
- (2018) Yochai Birnbaum et al. CARDIOVASCULAR DRUGS AND THERAPY
- Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect
- (2018) Samy Suissa DIABETES CARE
- Cardiovascular biomarkers in clinical studies of type 2 diabetes
- (2018) Maria P. A. Baldassarre et al. DIABETES OBESITY & METABOLISM
- Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin
- (2018) David Polidori et al. DIABETES OBESITY & METABOLISM
- Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
- (2018) Mikhail Kosiborod et al. DIABETES OBESITY & METABOLISM
- Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice
- (2018) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
- (2018) Sarah J. Mancini et al. Scientific Reports
- Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis
- (2018) Muhammad Shariq Usman et al. European Journal of Preventive Cardiology
- SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
- (2018) Robert M Bell et al. Lancet Diabetes & Endocrinology
- Short-term sustained hyperglycaemia fosters an archetypal senescence-associated secretory phenotype in endothelial cells and macrophages
- (2018) Francesco Prattichizzo et al. Redox Biology
- Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
- (2017) Tsung-Ming Lee et al. FREE RADICAL BIOLOGY AND MEDICINE
- Mechanisms linking empagliflozin to cardiovascular and renal protection
- (2017) Pasquale Perrone-Filardi et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice
- (2017) Yusuke Nakatsu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Role of NLRP3 Inflammasomes in Atherosclerosis
- (2017) Tadayoshi Karasawa et al. Journal of Atherosclerosis and Thrombosis
- A Metabolomic Signature of Acute Caloric Restriction
- (2017) Tinh-Hai Collet et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Inflammation, metaflammation and immunometabolic disorders
- (2017) Gökhan S. Hotamisligil NATURE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease
- (2017) Min Wei et al. Science Translational Medicine
- Effects of Ketogenic Diets on Cardiovascular Risk Factors: Evidence from Animal and Human Studies
- (2017) Christophe Kosinski et al. Nutrients
- Soluble Uric Acid Activates the NLRP3 Inflammasome
- (2017) Tarcio Teodoro Braga et al. Scientific Reports
- IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus
- (2017) Concepción Peiró et al. Frontiers in Pharmacology
- The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
- (2017) Sebastian Steven et al. Redox Biology
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
- (2017) Liang Xu et al. EBioMedicine
- Glucagon and heart in type 2 diabetes: new perspectives
- (2016) Antonio Ceriello et al. Cardiovascular Diabetology
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
- (2016) François Briand et al. DIABETES
- Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysis
- (2016) Edoardo Mannucci et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan
- (2015) Sebastian Brandhorst et al. Cell Metabolism
- Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
- (2015) A.J. Scheen et al. DIABETES & METABOLISM
- Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels
- (2015) C. D. Sjöström et al. DIABETES OBESITY & METABOLISM
- The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease
- (2015) Yun-Hee Youm et al. NATURE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding EMPA-REG OUTCOME
- (2015) Antonio Ceriello et al. Lancet Diabetes & Endocrinology
- SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
- (2014) Yukihiro Chino et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Increased Th1 and suppressed Th2 serum cytokine levels in subjects with diabetic coronary artery disease
- (2014) Haridoss Madhumitha et al. Cardiovascular Diabetology
- β-hydroxybutyrate: Much more than a metabolite
- (2014) John C. Newman et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Metabolic Impairment in Heart Failure
- (2014) Wolfram Doehner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
- (2014) Matthias Oelze et al. PLoS One
- The β-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages
- (2014) Mahbubur Rahman et al. Nature Communications
- Circulating Inflammatory Markers and the Risk of Vascular Complications and Mortality in People With Type 2 Diabetes and Cardiovascular Disease or Risk Factors: The ADVANCE Study
- (2013) G. Lowe et al. DIABETES
- Stabilization of atherosclerotic plaques: an update
- (2013) S. Yla-Herttuala et al. EUROPEAN HEART JOURNAL
- Ketone bodies as signaling metabolites
- (2013) John C. Newman et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies
- (2012) LANCET
- Intermittent fasting during Ramadan attenuates proinflammatory cytokines and immune cells in healthy subjects
- (2012) “Mo'ez Al-Islam” E. Faris et al. NUTRITION RESEARCH
- Suppression of Oxidative Stress by -Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
- (2012) T. Shimazu et al. SCIENCE
- Macrophages in the Pathogenesis of Atherosclerosis
- (2011) Kathryn J. Moore et al. CELL
- Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells
- (2011) Martina Lukasova et al. JOURNAL OF CLINICAL INVESTIGATION
- The Inflammasome in Atherosclerosis and Type 2 Diabetes
- (2011) S. L. Masters et al. Science Translational Medicine
- Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
- (2011) Gian Paolo Fadini et al. VASCULAR PHARMACOLOGY
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
- (2010) Peter Duewell et al. NATURE
- The role of IL-1 in the pathogenesis of heart disease
- (2009) Marcin Bujak et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies
- (2008) Marwan Maalouf et al. BRAIN RESEARCH REVIEWS
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
- (2008) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now